查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088704

核子醫學市場：2026-2032年全球市場預測（依產品類型、給藥方法、應用、應用領域及最終用戶分類）

Nuclear Medicine Market by Product Type, Mode Of Administration, Usage, Application, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核醫市場規模將成長至 238.8 億美元，複合年成長率為 9.36%。

主要市場統計數據
基準年 2025 127.6億美元
預計年份：2026年 139.3億美元
預測年份 2032 238.8億美元
複合年成長率 (%) 9.36%

核子醫學正從主要著重於診斷的專科轉型為整合PET/CT、SPECT/CT、放射性藥物治療、伴隨診斷和個人化劑量測定的精準醫療平台。腫瘤學、循環系統、神經病學、內分泌學和感染疾病影像學領域強勁的臨床需求推動了這一領域的發展。Technetium-99m仍是SPECT的主要放射性示蹤劑，而氟-18、鎵-68、銅-64、鋯-89、碘-131、鎦-177和錒-225則在更高價值的診斷和治療應用方面發揮重要作用。

檢驗的公共衛生數據凸顯了對核醫學服務的長期需求。根據世界衛生組織/國際癌症研究機構 (WHO/IARC) 2022 年全球癌症風險評估資料庫(GLOBOCAN 2022)，全球每年新增癌症病例約 2,000 萬例，癌症相關死亡病例約 970 萬例；同時，世界衛生組織估計全球有超過 5,500 萬人患有失智症。此外，世界衛生組織報告稱，心血管疾病仍然是全球首要死因，這凸顯了對心肌灌注顯像、分子顯像、放射性示踪劑研發、靶向放射性核素治療以及可擴展放射性藥物生產基礎設施的持續需求。

核子醫學領域的變革性變化

核子醫學領域最顯著的變化是治療診斷學的興起，它利用同一生物標的進行診斷、病患篩選、治療和療效監測。美國食品藥物管理局（FDA）批准治療診斷學 （Lu-177）鎦用於治療生長抑制素受體陽性神經內分泌腫瘤，以及鎦（Lu-177）雙匹肽四西坦用於治療PSMA陽性前列腺癌，這些都支持了靶向放射性藥物治療的臨床和商業性模式的有效性。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善影像重建、衰減校正、病灶檢測、器官分割、定量 PET/SPECT 分析和工作流程優先排序，進一步提升了核子醫學的價值。美國醫療設備清單中包含數百種已通過核准的產品，其中放射學領域是最大的類別，這表明監管機構已接受演算法驅動的影像工作流程。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

北美憑藉其先進的PET/CT技術、美國FDA對放射性藥物嚴格的核准流程、完善的核醫學影像檢查醫保報銷機制，以及在前列腺癌、神經內分泌腫瘤、循環系統和神經系統疾病領域活躍的臨床試驗網路，繼續保持著核醫學領先地區的地位。在歐洲，成熟的醫院基礎設施、歐洲藥品管理局（EMA）的監管、歐洲核醫學協會的臨床指南以及強大的放射性藥物研究體系，共同推動了核醫學的發展。此外，歐盟的跨境監管協調和同位素計劃也為標準化和供應穩定提供了支持。

主要區域分析：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

七國集團（G7）憑藉其先進的醫院基礎設施、監管能力、同位素生產技術、學術臨床試驗網路以及支持PET/CT、SPECT/CT和放射性藥物療法的保險報銷機制，在應用高價值核醫學技術方面佔據顯著佔有率。北約市場與北美和歐洲的醫療保健系統高度重疊，在這些地區，核子醫學透過腫瘤影像、心臟灌注影像、骨骼掃描和感染疾病評估等手段，為軍人、退伍軍人和一般民眾提供醫療保健服務。

主要核子醫學市場國家的關鍵洞察

美國在放射性藥物創新、FDA批准的治療診斷學、PET成像和臨床開發方面發揮主導作用，而加拿大則在同位素技術、迴旋加速器網路和學術核醫學研究方面做出貢獻。墨西哥和巴西是拉丁美洲的重要市場，這兩個國家不斷擴大的癌症治療能力正在推動對PET/CT和SPECT的需求。英國、德國、法國、義大利和西班牙擁有成熟的核子醫學網路，其中德國和法國尤其在放射性藥物的研究、生產、臨床指導和醫院部署方面具有顯著影響力。

為行業領導者提供的實用建議

產業領導者應優先發展治療診斷學產品組合，確保同位素的穩定供應，並培養生產差異化放射性藥物的能力。與醫院、迴旋加速器營運商、發生器供應商、學術機構、合約研發生產機構（CDMO）建立合作關係，可消除生產瓶頸，加速臨床應用。

調查方法

本執行摘要是基於公開檢驗的二手研究和交叉檢驗的行業資訊。主要資訊來源包括世界衛生組織、國際癌症研究機構全球癌症聯盟、國際原子能機構、經濟合作暨發展組織、美國食品藥物管理局、歐洲藥品管理局、歐洲核醫學協會、美國核子醫學與藥物濫用監測學會、各國衛生機構、同行評審的臨床文獻、法規核准資料庫以及公開的機構資訊披露。

結論

核子醫學正進入高價值的臨床成長階段，這主要得益於精準腫瘤學、治療診斷學、人工智慧影像以及更早期、更準確的疾病表徵的需求。 PSMA靶向和生長抑制素受體靶向放射性藥物的臨床檢驗，正推動該領域從一個專注於特定成像領域的細分市場，發展成為一個涵蓋診斷、治療選擇和治療反應監測的綜合性領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 核醫市場：依產品類型分類

  • 診斷用放射性藥物
    • 正子斷層掃描（PET）同位素
    • 單光子發射電腦斷層掃描（SPECT）用同位素
  • 治療性核子醫學
    • 用於近距離放射的同位素
      • 銫-131
      • 碘-125
      • 銥-192
      • 鈀-103
    • 放射性藥物療法
      • α粒子發射材料
      • BETA射線放射體

第8章 核子醫學市場：依給藥途徑分類

  • 靜脈注射
  • 口服

第9章 核子醫學市場：依用途分類

  • 診斷程序
    • PET掃描儀
      • 模擬PET
      • 數字PET
    • SPECT掃描儀
  • 治療

第10章 核子醫學市場：依應用領域分類

  • 循環系統
  • 內分泌學
  • 胃腸病學
  • 神經病學
  • 腫瘤學
  • 整形外科
  • 肺科

第11章 核子醫學市場：依最終用戶分類

  • 學術研究機構
  • 診斷中心
  • 醫院
    • 公立醫院
    • 私立醫院

第12章 核子醫學市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 核醫市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 核子醫學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • 3B Pharmaceuticals GmbH
  • Actinium Pharmaceuticals, Inc.
  • BJ Madan & Co.
  • Bayer AG
  • Bracco SpA
  • BWX Technologies, Inc.
  • Clarity Pharmaceuticals
  • Curium
  • Eli Lilly and Company
  • GE HealthCare
  • IBA
  • Institute of Isotopes Co., Ltd
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Medi-Radiopharma Co., Ltd.
  • Nordion
  • Northstar Medical Technologies LLC
  • Novartis AG
  • Nusano, Inc.
  • PeptiDream Inc.
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Siemens Healthineers AG
  • Sinotau Pharmaceuticals Group
  • South African Nuclear Energy Corporation
  • State Atomic Energy Corporation Rosatom
  • Thor Medical AS by Nordic Nanovector ASA
Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market is projected to grow by USD 23.88 billion at a CAGR of 9.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.76 billion
Estimated Year [2026] USD 13.93 billion
Forecast Year [2032] USD 23.88 billion
CAGR (%) 9.36%

Nuclear medicine is moving from a primarily diagnostic specialty toward an integrated precision medicine platform that combines PET/CT, SPECT/CT, radiopharmaceutical therapy, companion diagnostics, and patient-specific dosimetry. The field benefits from strong clinical demand in oncology, cardiology, neurology, endocrinology, and infection imaging, with technetium-99m remaining the workhorse for SPECT and fluorine-18, gallium-68, copper-64, zirconium-89, iodine-131, lutetium-177, and actinium-225 supporting higher-value diagnostic and therapeutic use cases.

Verified public health data reinforces the long-term need for nuclear medicine services. The WHO/IARC GLOBOCAN 2022 database reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide, while WHO estimates more than 55 million people live with dementia globally. Cardiovascular disease also remains the leading cause of death worldwide, according to WHO, supporting sustained demand for myocardial perfusion imaging, molecular imaging, radiotracer development, targeted radionuclide therapy, and scalable radiopharmacy infrastructure.

Transformative Shifts in the Nuclear Medicine Landscape

The most important shift in the nuclear medicine landscape is the rise of theranostics, where the same biological target is used for diagnosis, patient selection, therapy, and response monitoring. FDA approvals such as lutetium Lu-177 dotatate for somatostatin receptor-positive neuroendocrine tumors and lutetium Lu-177 vipivotide tetraxetan for PSMA-positive prostate cancer have validated clinical and commercial models for targeted radiopharmaceutical therapy.

At the same time, supply chain resilience has become a strategic priority. Molybdenum-99 and technetium-99m availability depends on a limited global production network, while short half-life PET isotopes require localized cyclotron, generator, or distribution capacity. Hospitals, radiopharmacies, and manufacturers are therefore investing in generator networks, automated synthesis, quality control systems, cold-kit innovation, workforce training, and regional isotope production to reduce disruption risk and improve patient access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of nuclear medicine by improving image reconstruction, attenuation correction, lesion detection, organ segmentation, quantitative PET/SPECT analysis, and workflow prioritization. The FDA public list of AI/ML-enabled medical devices includes hundreds of cleared products, with radiology representing the largest category, demonstrating regulatory acceptance of algorithm-supported imaging workflows.

In nuclear medicine, AI is especially relevant because quantitative accuracy directly affects staging, therapy selection, and dosimetry. AI-enabled tools can reduce scan time, support low-dose protocols, harmonize multi-center trial data, assist PSMA and somatostatin receptor lesion assessment, and automate absorbed-dose calculations for radionuclide therapy. The cumulative impact is a shift from visual interpretation toward reproducible, data-rich molecular imaging that supports precision oncology, clinical trial efficiency, and value-based care.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a leading nuclear medicine region due to advanced PET/CT adoption, a strong FDA pathway for radiopharmaceutical approvals, established reimbursement for many nuclear imaging procedures, and active clinical trial networks in prostate cancer, neuroendocrine tumors, cardiology, and neurology. Europe combines mature hospital infrastructure with EMA oversight, European Association of Nuclear Medicine clinical guidance, and strong radiopharmaceutical research, while European Union cross-border regulatory coordination and isotope initiatives support standardization and supply security.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in cancer centers, cyclotrons, PET/CT capacity, and domestic isotope capabilities to address rising oncology, cardiovascular, and neurological disease burdens. Latin America, led by Brazil and Mexico, shows rising demand but faces uneven access to cyclotrons, radiopharmacies, trained specialists, and reimbursement. The Middle East is building specialized oncology and diagnostic imaging capacity through hospital modernization programs, particularly in GCC countries, while Africa remains underpenetrated, with IAEA support, national cancer control initiatives, and public-sector hospital investment playing important roles in expanding access to radiopharmaceutical services.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

The G7 countries anchor a large share of high-value nuclear medicine adoption because they combine advanced hospital infrastructure, regulatory capacity, isotope production expertise, academic trial networks, and reimbursement systems that support PET/CT, SPECT/CT, and radiopharmaceutical therapy. NATO markets overlap significantly with North American and European healthcare systems, where nuclear medicine supports military, veteran, and civilian healthcare through oncology imaging, cardiac perfusion imaging, bone scintigraphy, and infection evaluation.

The European Union is central to radiopharmaceutical regulation, research funding, clinical standardization, and medical isotope supply security discussions. BRICS countries are becoming increasingly important because Brazil, Russia, India, China, and South Africa represent large patient populations, nuclear science capabilities, and rising oncology investment. ASEAN countries are improving PET/CT and SPECT access as urban tertiary care expands, while the GCC is investing in premium hospital infrastructure, cancer care, advanced diagnostic imaging, and regional radiopharmacy capabilities to reduce dependence on imported services.

Key Country Insights Across Major Nuclear Medicine Markets

The United States leads in radiopharmaceutical innovation, FDA-approved theranostics, PET imaging, and clinical development, while Canada contributes isotope expertise, cyclotron networks, and academic nuclear medicine research. Mexico and Brazil are important Latin American markets where expanding oncology capacity supports PET/CT and SPECT demand. The United Kingdom, Germany, France, Italy, and Spain maintain mature nuclear medicine networks, and Germany and France are particularly influential in radiopharmaceutical research, manufacturing, clinical guidance, and hospital-based adoption.

Russia retains nuclear science and isotope capabilities, while China and India are scaling imaging capacity to meet large cancer and cardiovascular disease burdens. Japan and South Korea combine advanced imaging adoption with strong technology ecosystems, and Australia is notable for theranostics leadership, nuclear medicine training, and regional clinical research. Across the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia, and South Korea, access depends on reimbursement, isotope logistics, specialist workforce availability, radiation safety infrastructure, and hospital investment in PET/CT, SPECT/CT, cyclotrons, generators, and radiopharmacy systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize theranostic portfolio development, secure isotope sourcing, and differentiated radiopharmaceutical manufacturing capabilities. Partnerships with hospitals, cyclotron operators, generator suppliers, academic centers, and contract development and manufacturing organizations can reduce capacity bottlenecks and accelerate clinical adoption.

Commercial success also requires evidence generation beyond regulatory approval. Organizations should invest in real-world outcomes, health economics, dosimetry validation, AI-enabled quantification, clinician education, multidisciplinary tumor boards, and patient referral pathways. Building resilient cold-chain logistics, automated quality control, radiation safety programs, and reimbursement dossiers will be essential for scaling nuclear medicine from specialized centers to broader oncology and diagnostic networks.

Research Methodology

This executive summary is built from publicly verifiable secondary research and cross-validated industry intelligence. Core sources include WHO, IARC GLOBOCAN, IAEA, OECD, FDA, EMA, EANM, SNMMI, national health agencies, peer-reviewed clinical literature, regulatory approval databases, and publicly available institutional disclosures.

The methodology applies triangulation across disease burden, procedure demand, isotope availability, radiopharmaceutical approvals, technology adoption, reimbursement conditions, and regional infrastructure. Market interpretation focuses on verified indicators rather than unsupported estimates, with emphasis on clinical utility, supply chain feasibility, regulatory pathways, radiation safety, and commercialization readiness across nuclear medicine diagnostics and therapeutics.

Conclusion

Nuclear medicine is entering a high-value clinical growth phase driven by precision oncology, theranostics, AI-enabled imaging, and the need for earlier, more accurate disease characterization. Clinical validation of PSMA-targeted and somatostatin receptor-targeted radiopharmaceuticals has shifted the sector from niche imaging toward integrated diagnosis, therapy selection, and response monitoring.

The strongest opportunities will favor organizations that can combine scientific credibility, isotope security, manufacturing quality, data-driven workflows, radiation safety, and regional market access. As cancer, cardiovascular disease, and neurodegenerative disorders continue to create global healthcare pressure, nuclear medicine is positioned to become a core pillar of personalized diagnosis, treatment planning, and long-term patient management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nuclear Medicine Market, by Product Type

  • 7.1. Diagnostic Radiopharmaceuticals
    • 7.1.1. Positron Emission Tomography (PET) Isotopes
    • 7.1.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
  • 7.2. Therapeutic Nuclear Medicine
    • 7.2.1. Brachytherapy Isotopes
      • 7.2.1.1. Cesium-131
      • 7.2.1.2. Iodine-125
      • 7.2.1.3. Iridium-192
      • 7.2.1.4. Palladium-103
    • 7.2.2. Radiopharmaceutical Therapy
      • 7.2.2.1. Alpha Emitters
      • 7.2.2.2. Beta Emitters

8. Nuclear Medicine Market, by Mode Of Administration

  • 8.1. Intravenous Injection
  • 8.2. Oral Ingestion

9. Nuclear Medicine Market, by Usage

  • 9.1. Diagnostic Procedure
    • 9.1.1. PET Scanners
      • 9.1.1.1. Analog PET
      • 9.1.1.2. Digital PET
    • 9.1.2. SPECT Scanners
  • 9.2. Therapeutic Procedure

10. Nuclear Medicine Market, by Application

  • 10.1. Cardiology
  • 10.2. Endocrinology
  • 10.3. Gastroenterology
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Orthopedics
  • 10.7. Pulmonology

11. Nuclear Medicine Market, by End Users

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
    • 11.3.1. Government Hospitals
    • 11.3.2. Private Hospitals

12. Nuclear Medicine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Nuclear Medicine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Medicine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. 3B Pharmaceuticals GmbH
  • 16.2. Actinium Pharmaceuticals, Inc.
  • 16.3. B J Madan & Co.
  • 16.4. Bayer AG
  • 16.5. Bracco S.p.A.
  • 16.6. BWX Technologies, Inc.
  • 16.7. Clarity Pharmaceuticals
  • 16.8. Curium
  • 16.9. Eli Lilly and Company
  • 16.10. GE HealthCare
  • 16.11. IBA
  • 16.12. Institute of Isotopes Co., Ltd
  • 16.13. Isotopia Molecular Imaging Ltd.
  • 16.14. Jubilant Pharma Limited
  • 16.15. Lantheus Holdings, Inc.
  • 16.16. Medi-Radiopharma Co., Ltd.
  • 16.17. Nordion
  • 16.18. Northstar Medical Technologies LLC
  • 16.19. Novartis AG
  • 16.20. Nusano, Inc.
  • 16.21. PeptiDream Inc.
  • 16.22. Radiopharm Theranostics Limited
  • 16.23. SHINE Technologies, LLC
  • 16.24. Siemens Healthineers AG
  • 16.25. Sinotau Pharmaceuticals Group
  • 16.26. South African Nuclear Energy Corporation
  • 16.27. State Atomic Energy Corporation Rosatom
  • 16.28. Thor Medical AS by Nordic Nanovector ASA

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CESIUM-131 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CESIUM-131 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CESIUM-131 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IODINE-125 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IODINE-125 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IODINE-125 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IRIDIUM-192 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IRIDIUM-192 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PALLADIUM-103 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PALLADIUM-103 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BETA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL INGESTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL INGESTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL INGESTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PET SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PET SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PET SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANALOG PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANALOG PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANALOG PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPECT SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPECT SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECT SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORTHOPEDICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORTHOPEDICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORTHOPEDICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PULMONOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PULMONOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PULMONOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 253. NATO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 353. RUSSIA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. RUSSIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. RUSSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 356. RUSSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)

T